BioCentury | Apr 16, 2007
Clinical News

CRD5: Phase I/II data

...Jan. 8). LPX thinks it can boost CRD5's efficacy and pH sensitivity with enteric coatings. Liponex Inc....
BioCentury | Jan 8, 2007
Clinical News

CRD5: Phase I/II amended

...dose-escalation study. Patients in the 1 and 3 g arms will continue to be treated. Liponex Inc....
BioCentury | Sep 11, 2006
Clinical News

CRD5: Completed Phase I/II enrollment

...LPX completed enrollment of 50 patients in a single-blinded, dose-escalating Canadian Phase I/II trial. Liponex Inc. (TSX:LPX...
BioCentury | Mar 6, 2006
Clinical News

CRD5: Phase I/II start

...will begin in the third quarter a dose-ranging, Canadian Phase I/II trial in 50 patients. Liponex Inc....
BioCentury | Oct 24, 2005
Company News

Liponex management update

Liponex Inc. (TSX:LPX), Ottawa, Ontario Business: Cardiovascular, Cancer, Infectious Hired: Kenneth Sokoll as VP of drug development, formerly VP of vaccine product development at United Biomedical Inc. WIR Staff cancer Cardiovascular Infectious...
BioCentury | Sep 12, 2005
Clinical News

CRD5: Start Phase II

...includes a small amount of a non-medicinal ingredient commonly used in food and drug products. Liponex Inc....
BioCentury | Aug 8, 2005
Finance

IPO queue

...Genomic Health 7/18/05 TBD TBD Up to $75M Intarcia 2/7/05 TBD TBD Up to $86.3M Liponex...
BioCentury | May 25, 2005
Financial News

Liponex files for IPO

...efforts basis through Jennings Capital; Canaccord Capital; Haywood Securities; Dundee Securities; and Wellington West Capital. Liponex...
BioCentury | Oct 25, 2004
Clinical News

CRD5: Phase I data

...Ic was double-blind and placebo-controlled. Data were presented at the Canadian Lipoprotein Conference in Alberta. Liponex Inc....
Items per page:
1 - 9 of 9
BioCentury | Apr 16, 2007
Clinical News

CRD5: Phase I/II data

...Jan. 8). LPX thinks it can boost CRD5's efficacy and pH sensitivity with enteric coatings. Liponex Inc....
BioCentury | Jan 8, 2007
Clinical News

CRD5: Phase I/II amended

...dose-escalation study. Patients in the 1 and 3 g arms will continue to be treated. Liponex Inc....
BioCentury | Sep 11, 2006
Clinical News

CRD5: Completed Phase I/II enrollment

...LPX completed enrollment of 50 patients in a single-blinded, dose-escalating Canadian Phase I/II trial. Liponex Inc. (TSX:LPX...
BioCentury | Mar 6, 2006
Clinical News

CRD5: Phase I/II start

...will begin in the third quarter a dose-ranging, Canadian Phase I/II trial in 50 patients. Liponex Inc....
BioCentury | Oct 24, 2005
Company News

Liponex management update

Liponex Inc. (TSX:LPX), Ottawa, Ontario Business: Cardiovascular, Cancer, Infectious Hired: Kenneth Sokoll as VP of drug development, formerly VP of vaccine product development at United Biomedical Inc. WIR Staff cancer Cardiovascular Infectious...
BioCentury | Sep 12, 2005
Clinical News

CRD5: Start Phase II

...includes a small amount of a non-medicinal ingredient commonly used in food and drug products. Liponex Inc....
BioCentury | Aug 8, 2005
Finance

IPO queue

...Genomic Health 7/18/05 TBD TBD Up to $75M Intarcia 2/7/05 TBD TBD Up to $86.3M Liponex...
BioCentury | May 25, 2005
Financial News

Liponex files for IPO

...efforts basis through Jennings Capital; Canaccord Capital; Haywood Securities; Dundee Securities; and Wellington West Capital. Liponex...
BioCentury | Oct 25, 2004
Clinical News

CRD5: Phase I data

...Ic was double-blind and placebo-controlled. Data were presented at the Canadian Lipoprotein Conference in Alberta. Liponex Inc....
Items per page:
1 - 9 of 9